鑽石舞台

Patients with cancer are atincreased risk of SARA-CoV-2infection or developing severe COVID-19 cases due to the malignancy orimmunosuppressive therapy, but they are generally excluded from the targetpopulation for COVID-19vaccination. In general, inactivated vaccines are safe and immunogenic for patients with cancer, butlive attenuated vaccines are not recommended.The study suggested thatthe safety of the mRNA COVID-19 vaccine in cancer patients is similar to thatin healthy people, but the immunogenicity is slightly weaker, and a booster dosemay be needed. This paper aims to summarize the results of COVID-19 vaccineclinical studies conducted in cancer patients worldwide and the relevantguidelines released by authorities, so as to provide evidence for promotingCOVID-19 vaccination for cancer patients.

癌症患者因惡性腫瘤或免疫抑制治療而導致感染新冠或發展為重症新冠病例的風險增加，但他們通常被排除在新冠疫苗接種的目標人群之外。一般來說，滅活疫苗對於癌症患者是安全且具有免疫原性的，但不推薦他們接種減毒活疫苗。研究表明，mRNA新冠疫苗在癌症患者中的安全性與在健康人中的安全性相似，但免疫原性稍弱，可能需要加強免疫。本文旨在總結國內外在癌症患者中開展的新冠疫苗臨床研究的結果和權威機構發布的相關指南，為促進癌症患者接種新冠疫苗提供依據。